Exclusive: Ferring Pharma sees 2015 revenue up 20% boosted by strong US dollar
Ferring Pharma expects a 20% increase in 2015 full-year revenue on the back of a stronger US dollar, chief operating officer Michel Pettigrew, told The Pharma Letter in an interview.
“We are looking at 1.7 billion euros [$1.93 billion] to 1.8 billion euros in revenue. [It] is going to be good because first of all the US dollar has strengthened so much against the euro [and] the US is our fastest growing market,” Pettigrew said.
The Saint-Prex, Switzerland-based privately-held company reported 2014 revenue of 1.5 billion euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze